Skip to main content
. Author manuscript; available in PMC: 2017 Mar 28.
Published in final edited form as: Leukemia. 2016 Sep 28;31(3):678–687. doi: 10.1038/leu.2016.260

Figure 5. Co-treatment with JQ1 and JAK2 inhibitors synergistically induces cell death in patient-derived CD34+ sAML cells.

Figure 5

A. Patient-derived (PD) CD34+ sAML cells and normal CD34+ cells were treated with the indicated concentrations of JQ1 for 48 hours. At the end of treatment, the % of PI-positive, non-viable cells was determined by flow cytometry. Columns, mean loss of cell viability; Bars, standard error of the mean. B-C. Patient-derived CD34+ sAML cells (n=2) were treated with JQ1 and ruxolitinib for 48 hours. The % of non-viable cells was determined by propidium iodide (PI) staining and flow cytometry. Median dose effect and isobologram analyses were performed utilizing CompuSyn, assuming mutual exclusivity. Combination index (CI) values less than 1.0 indicate a synergistic interaction of the two agents in the combination.